Method for preparing IgA dimer

By co-transfecting mammalian cells, the self-shearing peptides in heavy and light chain expression plasmids were used to solve the problems of low yield and stability of IgA antibodies, and the production of high-efficiency and high-purity IgA dimers were achieved, which promoted the production of high-quality high-purity IgA dimers. Clinical and industrial applications of IgA antibodies.

CN118995809AActive Publication Date: 2024-11-22TSINGHUA UNIVERSITY

Patent Information

Application Number
CN202310555265.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-22
Estimated Expiration
2043-05-17

AI Technical Summary

Technical Problem

The prior art has problems of low yield and batch instability in the preparation of IgA antibodies, which hinders the advancement of IgA antibodies to the clinical and industrial directions.

Method used

By preparing heavy and light chain expression plasmids, including J chain, self-shelf peptide, secretory signal peptide and IgA antibody chain, mammalian cells were co-transfected, and protein expression was used by 2A self-shelf peptide to achieve efficient production of IgA double Mixture.

Benefits of technology

The production of a large number of high-purity IgA dimers has been achieved, and the research and clinical promotion of IgA antibodies has been promoted. It has important theoretical guidance value and wide application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004232766230000011
    Figure HDA0004232766230000011
  • Figure HDA0004232766230000012
    Figure HDA0004232766230000012
  • Figure HDA0004232766230000021
    Figure HDA0004232766230000021
Patent Text Reader

Abstract

The invention discloses a method for preparing an IgA (Immunoglobulin A) dimer. The invention provides a method for preparing an IgA dimer. The method comprises the following steps: (1) preparing a heavy chain expression plasmid and a light chain expression plasmid; the heavy chain expression plasmid is used for expressing heavy chain fusion protein; the heavy chain fusion protein sequentially comprises the following elements: a J chain, a self-shearing peptide, a secreting type signal peptide and an IgA antibody heavy chain, the light chain expression plasmid is used for expressing light chain fusion protein; the light chain fusion protein sequentially comprises the following elements: a secretory signal peptide and an IgA antibody light chain, and (2) co-transfecting mammalian cells with the heavy chain expression plasmid and the light chain expression plasmid, and culturing to obtain the IgA dimer. By adopting the method disclosed by the invention, a large amount of high-purity dimer IgA can be produced. The method is used for expression production of the dimer IgA, and has important theoretical guidance value and wide application prospect in research, clinical popularization, industrial production and the like of the dimer IgA antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and relates to a method for preparing IgA dimers. Background Art

[0002] The new coronavirus is mainly transmitted through the respiratory tract, and the antigen on its surface is mainly its spike protein, and its antigen receptor is angiotensin-converting enzyme 2 (ACE2). The virus invades the human body mainly through infection mediated by contact between spike and ACE2.

[0003] The main types of antibodies in the human body are divided into three types: IgG, IgA and IgM. The content of IgA antibodies in the blood is second only to IgG. There are two main forms of IgA, namely IgA monomer (mIgA) and IgA dimer (dIgA) formed by J chain. In the upper respiratory tract, such as the nasal cavity, IgA dimer is secreted into the upper respiratory tract together with the secretory component (SC), playing a vital role in the human body's defense against the invasion of pathogens in the respiratory tract.

[0004] Research on IgA antibodies is of great significance for preventing and treating novel coronavirus infection or other respiratory pathogen invasion. However, what worries everyone is that IgA antibodies have diverse components and complex expressions. The existing expression methods have difficulties such as low yield and unstable expression batches, which hinder the advancement of IgA antibody research in the clinical direction. Summary of the invention

[0006] The object of the present invention is to provide a method for preparing IgA dimers.

[0007] The present invention provides a method for preparing IgA dimer, comprising the following steps:

[0008] (1) preparing heavy chain expression plasmid and light chain expression plasmid;

[0009] The heavy chain expression plasmid is used to express a heavy chain fusion protein; the heavy chain fusion protein includes the following elements in sequence: a J chain, a self-cleavage peptide, a secretory signal peptide, and an IgA antibody heavy chain;

[0010] The light chain expression plasmid is used to express a light chain fusion protein; the light chain fusion protein includes the following elements in sequence: a secretory signal peptide and an IgA antibody light chain;

[0011] (2) The heavy chain expression plasmid and the light chain expression plasmid are co-transfected into mammalian cells, which are then cultured to obtain IgA dimers.

[0012] Specifically, the heavy chain fusion protein is composed of the following elements in sequence: J chain, self-cleavage peptide, secretory signal peptide, and IgA antibody heavy chain.

[0013] Specifically, the light chain fusion protein is composed of the following elements in sequence: a secretory signal peptide, an IgA antibody light chain;

[0014] The self-cleaving peptide is a 2A self-cleaving peptide.

[0015] The 2A self-cleaving peptide refers to a polypeptide comprising "VEENPGP".

[0016] "VEENPGP" is the active center of the 2A self-cleaving peptide.

[0017] The 2A self-cleaving peptide may specifically be a T2A self-cleaving peptide or a P2A self-cleaving peptide.

[0018] The cleavage site of the self-cleaving peptide is located between the amino acid residue G and the amino acid residue P of "VEENPGP".

[0019] Specifically, the self-cleaving peptide is shown in positions 160-177 of SEQ ID NO:1.

[0020] Specifically, in the heavy chain fusion protein, the secretory signal peptide is as shown in positions 178-197 of SEQ ID NO: 1;

[0021] Specifically, in the light chain fusion protein, the secretory signal peptide is shown at positions 1 to 19 in SEQ ID NO:3.

[0022] Specifically, the J chain is shown at positions 1-159 in SEQ ID NO:1.

[0023] The IgA antibody heavy chain consists of a heavy chain variable region and a heavy chain constant region from upstream to downstream.

[0024] The IgA antibody light chain consists of a light chain variable region and a light chain constant region from upstream to downstream.

[0025] Specifically, the heavy chain constant region of the IgA antibody heavy chain is shown at positions 325-677 in SEQ ID NO: 1;

[0026] Specifically, the light chain constant region of the IgA antibody light chain is shown at positions 127-233 in SEQ ID NO:3.

[0027] Specifically, the heavy chain variable region of the IgA antibody heavy chain is shown at positions 198-324 in SEQ ID NO:1.

[0028] Specifically, the light chain variable region of the IgA antibody light chain is shown at positions 20-126 in SEQ ID NO:3.

[0029] Specifically, the heavy chain variable region of the IgA antibody heavy chain is shown in SEQ ID NO: 8

[0030] Specifically, the light chain variable region of the IgA antibody light chain is shown in SEQ ID NO:10.

[0031] Specifically, the heavy chain variable region of the IgA antibody heavy chain is shown in SEQ ID NO: 12

[0032] Specifically, the light chain variable region of the IgA antibody light chain is shown in SEQ ID NO:14.

[0033] The heavy chain expression plasmid contains a DNA molecule encoding the heavy chain fusion protein.

[0034] The light chain expression plasmid contains a DNA molecule encoding the light chain fusion protein.

[0035] The DNA molecule encoding the heavy chain fusion protein includes the following elements in sequence: a DNA segment encoding the J chain, a DNA segment encoding the self-cleavage peptide, a DNA segment encoding the secretory signal peptide, and a DNA segment encoding the IgA antibody heavy chain. The DNA molecule encoding the heavy chain fusion protein is composed of the following elements in sequence: a DNA segment encoding the J chain, a DNA segment encoding the self-cleavage peptide, a DNA segment encoding the secretory signal peptide, and a DNA segment encoding the IgA antibody heavy chain.

[0036] The DNA molecule encoding the light chain fusion protein includes the following elements in sequence: a DNA segment encoding a secretory signal peptide, and a DNA segment encoding an IgA antibody light chain. The DNA molecule encoding the light chain fusion protein is composed of the following elements in sequence: a DNA segment encoding a secretory signal peptide, and a DNA segment encoding an IgA antibody light chain.

[0037] Specifically, the DNA segment encoding the J chain is shown in positions 1-477 of SEQ ID NO:2.

[0038] Specifically, the DNA segment encoding the self-cleaving peptide is shown in positions 478-531 of SEQ ID NO:2.

[0039] Specifically, the DNA segment encoding the secretory signal peptide is shown in positions 532-591 of SEQ ID NO:2.

[0040] Specifically, the DNA segment encoding the secretory signal peptide is shown in positions 1 to 57 of SEQ ID NO:4.

[0041] Specifically, the DNA segment encoding the heavy chain constant region of the IgA antibody heavy chain is shown at positions 973-2034 in SEQ ID NO:2.

[0042] Specifically, the DNA segment encoding the light chain constant region of the IgA antibody light chain is shown at positions 379-702 in SEQ ID NO:4.

[0043] Specifically, the DNA segment encoding the heavy chain variable region of the IgA antibody heavy chain is shown at positions 592-972 in SEQ ID NO:2.

[0044] Specifically, the DNA segment encoding the light chain variable region of the IgA antibody light chain is shown at positions 58-378 in SEQ ID NO:4.

[0045] Specifically, the DNA segment encoding the heavy chain variable region of the IgA antibody heavy chain is shown in SEQ ID NO:9.

[0046] Specifically, the DNA segment encoding the light chain variable region of the IgA antibody light chain is shown in SEQ ID NO: 11

[0047] Specifically, the DNA segment encoding the heavy chain variable region of the IgA antibody heavy chain is shown in SEQ ID NO: 13

[0048] Specifically, the DNA segment encoding the light chain variable region of the IgA antibody light chain is shown in SEQ ID NO: 15

[0049] The heavy chain expression plasmid may specifically be a recombinant plasmid obtained by inserting a DNA molecule encoding the heavy chain fusion protein into the multiple cloning site of a pCDNA3.4 vector.

[0050] The heavy chain expression plasmid can be specifically a recombinant plasmid obtained by replacing a small fragment between two multiple cloning sites (such as XBaI and AgeI restriction sites) of the pCDNA3.4 vector with a DNA molecule encoding the heavy chain fusion protein.

[0051] The light chain expression plasmid can specifically be a recombinant plasmid obtained by inserting a DNA molecule encoding the light chain fusion protein into the multiple cloning site of the pCDNA3.1 vector.

[0052] The light chain expression plasmid can be specifically a recombinant plasmid obtained by replacing a small fragment between two multiple cloning sites (BamHI and EcoRI restriction sites) of the pCDNA3.1 vector with a DNA molecule encoding the light chain fusion protein.

[0053] The present invention also embodies a kit for preparing IgA dimers, comprising any of the above-mentioned heavy chain expression plasmids and any of the above-mentioned light chain expression plasmids.

[0054] The kit also includes mammalian cells.

[0055] The IgA is composed of an IgA antibody heavy chain and an IgA antibody light chain.

[0056] The IgA antibody heavy chain is any one of the above.

[0057] The IgA antibody light chain is any of the above.

[0058] Any of the above mammalian cells may be 293 cells or cells derived therefrom.

[0059] Any of the above mammalian cells can specifically be 293F cells.

[0060] The present invention also protects the use of the kit in preparing IgA dimers.

[0061] The method of the present invention can produce a large amount of high-purity dimer IgA.

[0062] The invention is used for the expression and production of dimeric IgA, and has important theoretical guiding value and broad application prospects for the research, clinical promotion and industrial production of dimeric IgA antibodies. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 Schematic diagram of the expression strategy of Example 1 and Comparative Example 2.

[0064] Figure 2 This is the chromatogram of the small-scale SEC chromatography column used in Example 1.

[0065] Figure 3 The electrophoretic diagrams of reducing SDS-PAGE and non-reducing SDS-PAGE in Example 1 are shown.

[0066] Figure 4 This is the chromatogram of the small-scale SEC chromatography column used in Comparative Example 1.

[0067] Figure 5 This is the neutralization activity result diagram of Example 2.

[0068] Figure 6 This is the neutralization activity result diagram of Example 4. DETAILED DESCRIPTION

[0069] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0070] The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources. Unless otherwise specified, the quantitative tests in the following examples are set up for three repeated experiments, and the results are averaged. In the examples, the recombinant plasmids have been sequenced and verified. SMM 293-TII culture medium: Sino Biological Technology Co., Ltd., catalog number M293TII. PEI transfection reagent: PEI Max, Polysciences Biological Company, catalog number 24765. The pCDNA3.4 vector is a circular double-stranded DNA molecule, and the full sequence is shown in SEQ ID NO: 16. The pCDNA3.1 vector is a circular double-stranded DNA molecule, and the full sequence is shown in SEQ ID NO: 17.

[0071] hACE2-hela cells (ie "HeLa cell lines stably expressing theACE2molecules"), recorded in the following literature: Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Ch. en,P.,Liao,H.,Feng,Y.,Li,X.,Shi,X.,Zhang,Z.,Zhang,F.,Ding,Q.,Zhang,T.,Wang,X.&Zhang,L.Analysis of SARS-CoV-2 variant mutations reveal neutralization escape mechanisms and the ability to use ACE2receptors from additional species. Immunity 54, 1611-1621.e1615, doi:10.1016 / j.immuni.2021.06.003(2021).

[0072] Example 1: Preparation of Antibody 311 Using the Expression Strategy of the Present Invention

[0073] 1. Construction of recombinant plasmid

[0074] Schematic diagram of expression strategy Figure 1 A.

[0075] 1. Prepare a heavy chain expression plasmid and name it 311-2AHC plasmid.

[0076] The 311-2AHC plasmid is a recombinant plasmid obtained by replacing the small fragment between the XBaI and AgeI restriction sites in the pCDNA3.4 vector with the double-stranded DNA molecule shown in SEQ ID NO: 2. The double-stranded DNA molecule shown in SEQ ID NO: 2 encodes the protein shown in SEQ ID NO: 1.

[0077] In SEQ ID NO: 1, positions 1-159 constitute the J chain, positions 160-177 constitute the self-cleavage peptide, positions 178-197 constitute the IL2 signal peptide, positions 198-324 constitute the heavy chain variable region of antibody 311, and positions 325-677 constitute the heavy chain constant region of antibody 311. The self-cleavage peptide has a self-cleavage effect, and the signal peptide is removed, ultimately producing the following two proteins: the protein shown in positions 1-176 of SEQ ID NO: 1 (which contains the J chain), and the protein shown in positions 198-677 of SEQ ID NO: 1 (i.e., the heavy chain of antibody 311).

[0078] 2. Prepare a light chain expression plasmid and name it 311-LC plasmid.

[0079] The 311-LC plasmid is a recombinant plasmid obtained by replacing the small fragment between the BamHI and EcoRI restriction sites in the pCDNA3.1 vector with the double-stranded DNA molecule shown in SEQ ID NO: 4. The double-stranded DNA molecule shown in SEQ ID NO: 4 encodes the protein shown in SEQ ID NO: 3.

[0080] In SEQ ID NO: 3, positions 1-19 constitute the secretory signal peptide, positions 20-126 constitute the light chain variable region of antibody 311, and positions 127-233 constitute the light chain constant region of antibody 311. The signal peptide is removed, and the protein shown in positions 20-233 of SEQ ID NO: 3 (i.e., the light chain of antibody 311) is finally produced.

[0081] 2. Preparation of Antibody 311

[0082] 1. Add 5 ml PEI transfection reagent to 50 ml SMM 293-TII medium, add 1 mg 311-2AHC plasmid and 1 mg 311-LC plasmid, mix thoroughly and let stand for 15-20 minutes, then add to 1 L 293F cell suspension and culture for 96 hours. 293F cell suspension: 293F cells are suspended in SMM 293-TII medium at a cell density of (2-3) × 10 6 cells / ml.

[0083] 2. After completing step 1, collect the entire culture system, centrifuge at 4000 rpm, discard the cell pellet, and collect the supernatant (obtain about 1 L of supernatant in total).

[0084] 3. Take all the supernatant obtained in step 2 and use CaptureSelect TM IgA affinity matrix (Thermofisher, Cat. 194288005) was used for antibody purification according to its instructions. Specific steps: 2 ml CaptureSelect TM The IgA affinity matrix was incubated at 4°C overnight, and then the entire system was transferred to an empty chromatography column, washed with 10-20 ml PBS buffer (pH 7.2, 10 mM), and then eluted with 10 ml glycine-HCl buffer (pH 3.0, 0.1 M) and the eluate after passing through the column was collected.

[0085] 4. Take all the eluate collected in step 3, adjust the pH to 7, and then filter and sterilize with a 0.45 μm filter membrane and collect the filtrate, and then concentrate it with a Merck 30KD Amicon Ultra-15 centrifugal filter to obtain 3 ml of concentrated solution. The antibody protein concentration in the concentrated solution was detected by Thermo nanodrop, which was 3 mg / ml. Therefore, the total protein yield was 9 mg.

[0086] 5. Take 1 ml of the concentrate obtained in step 4 and load it on Superose TM 6Increase 10 / 300GL small-scale SEC chromatography column (Cytiva, Cat. 29091596), and then eluted with PBS buffer (pH 7.2, 10 mM). See the chromatogram Figure 2 , showing the characteristic peak of IgA dimer (according to the chromatography column and the expected molecular weight, the retention volume corresponding to the theoretical characteristic peak is in the range of 11-13 ml), and the characteristic peak intensity is as high as 800 mAU or more. The chromatogram shows that high-purity IgA dimer is obtained with a high yield. The post-column solution corresponding to the characteristic peak of IgA dimer is collected, which is the dIgA-311 antibody solution.

[0087] 6. Take the dIgA-311 antibody solution prepared in step 5 and perform reducing SDS-PAGE and non-reducing SDS-PAGE, respectively. The results are shown in Figure 3 . Figure 3 It can be observed that the antibody bands are concentrated and single, that is, the antibody solution contains high-purity IgA dimers.

[0088] Comparative Example 1: Preparation of Antibody 311 Using Traditional Method (Three-plasmid Expression Strategy)

[0089] 1. Construction of recombinant plasmid

[0090] 1. Prepare a heavy chain expression plasmid, named 311-HC plasmid.

[0091] The 311-HC plasmid is a recombinant plasmid obtained by replacing the small fragment between the XBaI and AgeI restriction sites in the pCDNA3.4 vector with a double-stranded DNA molecule shown in SEQ ID NO: 5.

[0092] In SEQ ID NO: 5, nucleotides 1 to 60 encode the IL2 signal peptide, and nucleotides 61 to 1503 encode the heavy chain of antibody 311.

[0093] 2. Prepare the J chain expression vector and name it Human-J plasmid.

[0094] The Human-J plasmid is a recombinant plasmid obtained by replacing the small fragment between the XBaI and AgeI restriction sites in the pCDNA3.4 vector with a double-stranded DNA molecule shown in SEQ ID NO: 6.

[0095] The DNA molecule shown in SEQ ID NO: 6 encodes the J chain.

[0096] 3. Light chain expression plasmid, i.e., the 311-LC plasmid prepared in Example 1.

[0097] 2. Preparation of Antibody 311

[0098] 1. Add 5 ml of PEI transfection reagent to 50 ml of SMM 293-TII medium, add 1 mg of 311-HC plasmid, 1 mg of Human-J plasmid and 1 mg of 311-LC plasmid, mix thoroughly and let stand for 15-20 minutes, then add to 1L of 293F cell suspension and culture for 96 hours. 293F cell suspension: 293F cells are suspended in SMM 293-TII medium with a cell density of (2-3)×10 6 cells / ml.

[0099] 2. Same as step 2 of Example 1.

[0100] 3. Same as step 3 of step 2 in embodiment 1.

[0101] 4. Same as 4 in step 2 of Example 1. The total protein yield was 0.8 mg.

[0102] 5. Same as step 5 of step 2 in embodiment 1.

[0103] Chromatogram Figure 4 , showing the characteristic peak of IgA dimer (according to the chromatography column and the expected molecular weight, the retention volume corresponding to the theoretical characteristic peak is in the range of 11-13 ml) and the characteristic peak of IgA monomer (according to the chromatography column and the expected molecular weight, the retention volume corresponding to the theoretical characteristic peak is in the range of 13-15 ml), and the intensity of the characteristic peak of IgA dimer does not exceed 100 mAU. It can be seen that the traditional method for preparing IgA dimer has low yield and low purity.

[0104] Comparative Example 2: Preparation of Antibody 311 Using Other Expression Strategies

[0105] 1. Construction of recombinant plasmid

[0106] Schematic diagram of expression strategy Figure 1 B.

[0107] 1. Prepare a heavy chain expression plasmid and name it as heavy chain control plasmid.

[0108] The heavy chain control plasmid is a recombinant plasmid obtained by replacing the small fragment between the XBaI and AgeI restriction sites in the pCDNA3.4 vector with a double-stranded DNA molecule shown in SEQ ID NO: 7.

[0109] In SEQ ID NO: 7, nucleotides 1-60 encode the IL2 signal peptide, nucleotides 61-1500 encode the heavy chain of antibody 311, nucleotides 1501-1554 encode the self-cleavage peptide, and nucleotides 1555-2034 encode the J chain.

[0110] 2. Light chain expression plasmid, i.e., the 311-LC plasmid prepared in Example 1.

[0111] 2. Preparation of Antibody 311

[0112] 1. Add 5 ml of PEI transfection reagent to 50 ml of SMM 293-TII medium, add 1 mg of heavy chain control plasmid and 1 mg of 311-LC plasmid, mix thoroughly and let stand for 15-20 minutes, then add to 1 L of 293F cell suspension and culture for 96 hours. 293F cell suspension: 293F cells are suspended in SMM 293-TII medium at a cell density of (2-3) × 10 6 cells / ml.

[0113] 2. Same as step 2 of Example 1.

[0114] 3. Same as step 3 of step 2 in embodiment 1.

[0115] 4. Same as 4 of step 2 of Example 1. The total protein yield was 100 μg.

[0116] Example 2: Functional verification of dIgA-311 antibody

[0117] 1. Preparation of novel coronavirus pseudovirus

[0118] The plasmid expressing the membrane protein of the novel coronavirus and the backbone plasmid pNL4-3R-E-luciferase were co-transfected into 293T cells, and after incubation, a pseudovirus of the novel coronavirus with infectivity but no replication ability was obtained, and its infectivity was similar to that of the live novel coronavirus. The backbone plasmid pNL4-3R-E-luciferase, i.e., the backbone plasmid pNL4-3R-E containing Luciferase (i.e., the vector with the luciferase gene containing backbone pNL4-3R-E in the literature) is recorded in the following literature: Wang Q, Liu L, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T, Zhang L. Cell Rep. 2019.

[0119] The coding gene of the novel coronavirus membrane protein was inserted between the BamHII and EcoRI restriction sites of the pcDNA3.1(+) vector to obtain a plasmid expressing the novel coronavirus membrane protein. The plasmid expressing the novel coronavirus membrane protein and the backbone plasmid pNL4-3R-E-luciferase were co-transfected into 293T cells, incubated at 37°C (using DMEM medium containing 10% fetal bovine serum), and the cell culture supernatant was collected 60 hours after transfection, which was the virus liquid containing the novel coronavirus pseudovirus. The coding gene of the membrane protein of the novel coronavirus wild strain (WT) is shown in SEQ ID NO: 18.

[0120] 2. Neutralization Activity Detection

[0121] 1. Take the dIgA-311 antibody solution prepared in Example 1 and dilute it with PBS buffer (pH 7.2, 10 mM) to obtain antibody dilutions of various concentrations.

[0122] 2. Take a 96-well cell culture plate and add 100 μl of antibody diluent and 50 μl of virus solution prepared in step 1 to each well (the virus concentration in 50 μl of virus solution is 1×10 4TCID50 / ml), 100 μl of PBS buffer (pH 7.2, 10 mM) and 50 μl of the virus solution prepared in step 1 were added to each well of the virus control well (the virus concentration in 50 μl of the virus solution was 1×10 4 TCID50 / ml), 100 μl PBS buffer (pH 7.2, 10 mM) and 50 μl DMEM medium containing 10% fetal bovine serum were added to each well of the cell control wells and incubated at 37°C for 1 hour.

[0123] 3. After completing step 2, take the cell culture plate and inoculate 100 μl of hACE2-hela cell suspension in each well (the solvent used to prepare the cell suspension is DMEM medium containing 10% fetal bovine serum, and the concentration of hACE2-hela cells in the cell suspension is 2×10 5 cells / ml) and incubated at 37°C for 64 hours.

[0124] 4. After completing step 3, take the cell culture plate, discard the supernatant, add 100 μl of lysis buffer (Novozyme Biotech, catalog number DD1204-03, follow the instructions) to each well, and incubate at 37°C for 5 minutes.

[0125] 5. After completing step 4, take the cell culture plate and detect the luciferase activity.

[0126] Multiple replicate wells were set up for each treatment.

[0127] Neutralization activity (%) = [1-(fluorescence intensity of the test group-fluorescence intensity of the cell control) / (fluorescence intensity of the virus control-fluorescence intensity of the cell control)] x 100%.

[0128] Neutralization activity results are shown in Figure 5 . Figure 5 Middle: The ordinate is the neutralization activity (%); the abscissa is the logarithm of the antibody concentration (μg / ml) to the base 10, and the antibody concentration refers to the antibody concentration in the mixed system consisting of 100 μl of antibody diluent and 50 μl of test virus solution in step 2.

[0129] Prism 5 software was used to calculate the antibody concentration at which the neutralization activity was 50%, i.e., the IC50 value of the antibody.

[0130] The IC50 value of the dIgA-311 antibody against the pseudovirus of the wild-type novel coronavirus is 1.5 ng / ml.

[0131] Example 3: Preparation of three antibodies using the expression strategy of the present invention

[0132] 1. Preparation of antibody dIgA-311

[0133] The method is the same as in Example 1.

[0134] 2. Preparation of Antibody dIgA-341

[0135] The only difference is the heavy chain expression plasmid and the light chain expression plasmid.

[0136] Compared with the 311-2AHC plasmid, the only difference in the heavy chain expression plasmid is that the coding sequence of the heavy chain variable region of antibody 311 (as shown in positions 592-972 in SEQ ID NO: 2) is replaced with the coding sequence of the heavy chain variable region of antibody 341 (as shown in SEQ ID NO: 9). The heavy chain variable region of antibody 341 is shown in SEQ ID NO: 8.

[0137] Compared with the 311-LC plasmid, the only difference of the light chain expression plasmid is that the coding sequence of the light chain variable region of antibody 311 (as shown in positions 58-378 in SEQ ID NO: 4) is replaced with the coding sequence of the light chain variable region of antibody 341 (as shown in SEQ ID NO: 11). The light chain variable region of antibody 341 is shown in SEQ ID NO: 10.

[0138] The rest is the same as in Example 1.

[0139] 3. Preparation of Antibody dIgA-335

[0140] Compared with the 311-2AHC plasmid, the only difference in the heavy chain expression plasmid is that the coding sequence of the heavy chain variable region of antibody 311 (as shown in positions 592-972 in SEQ ID NO: 2) is replaced with the coding sequence of the heavy chain variable region of antibody 335 (as shown in SEQ ID NO: 13). The heavy chain variable region of antibody 335 is shown in SEQ ID NO: 12.

[0141] Compared with the 311-LC plasmid, the only difference of the light chain expression plasmid is that the coding sequence of the light chain variable region of antibody 311 (as shown in positions 58-378 in SEQ ID NO: 4) is replaced with the coding sequence of the light chain variable region of antibody 335 (as shown in SEQ ID NO: 15). The light chain variable region of antibody 335 is shown in SEQ ID NO: 14.

[0142] The rest is the same as in Example 1.

[0143] In step 1, step 2 and step 3, the purity and yield of the antibodies are shown in Table 1.

[0144] Table 1 Comparison of expression results of three different IgA antibodies

[0145] Antibody Name Antibody expression volume Cultivation time Final antibody yield Antibody purity dIgA-311 800ml 96h 9.2mg >90% dIgA-341 800ml 96h 10.6mg >90% dIgA-335 800ml 96h 11.4mg >90%

[0146] Example 4: Functional verification of antibodies

[0147] The three antibodies prepared in Example 3 were functionally verified using the same method as in Example 2.

[0148] Results Figure 6 .

[0149] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. A method for preparing IgA dimer, comprising the following steps: (1) preparing heavy chain expression plasmid and light chain expression plasmid; The heavy chain expression plasmid is used to express a heavy chain fusion protein; the heavy chain fusion protein includes the following elements in sequence: a J chain, a self-cleavage peptide, a secretory signal peptide, and an IgA antibody heavy chain; The light chain expression plasmid is used to express a light chain fusion protein; the light chain fusion protein includes the following elements in sequence: a secretory signal peptide and an IgA antibody light chain; (2) The heavy chain expression plasmid and the light chain expression plasmid are co-transfected into mammalian cells, which are then cultured to obtain IgA dimers.

2. The method according to claim 1, Features: The cleavage site of the self-cleaving peptide is between the amino acid residue G and the amino acid residue P.

3. The method according to claim 1 or 2, Features: In the heavy chain fusion protein, the secretory signal peptide is as shown in positions 178-197 of SEQ ID NO: 1; In the light chain fusion protein, the secretory signal peptide is shown in positions 1 to 19 of SEQ ID NO:

3.

4. The method according to claim 1, 2 or 3, Features: The J chain is shown at positions 1 to 159 in SEQ ID NO:

1.

5. The method according to claim 1 or 2 or 3 or 4, Features: The self-cleaving peptide is shown at positions 160-177 in SEQ ID NO:

1.

6. The method according to claim 1 or 2 or 3 or 4 or 5, Features: The constant region of the IgA antibody heavy chain is shown at positions 325-677 in SEQ ID NO: 1; The constant region of the IgA antibody light chain is shown at positions 127 to 233 in SEQ ID NO:

3.

7. The method according to any one of claims 1 to 6, Features: The mammalian cells are 293F cells.

8. A kit for preparing IgA dimers, comprising a heavy chain expression plasmid and a light chain expression plasmid; The heavy chain expression plasmid is as described in any one of claims 1 to 6; The heavy and light chain expression plasmid is as described in any one of claims 1 to 6.

9. The kit according to claim 8, Features: The kit also includes mammalian cells.

10. Use of the kit according to claim 8 or 9 in the preparation of IgA dimers.

Citation Information

Patent Citations

  • Method for promoting massive secretion of functional IgA antibody

    CN110157701A

  • METHOD FOR PRODUCING POLYMER IgA ANTIBODY, AND POLYSPECIFIC POLYMER IgA ANTIBODY

    CN115397833A

  • Recombinant method for making multimeric proteins

    US20060121574A1

  • POLYMERIC IgA-TYPE RECOMBINANT ANTIBODY AND USE THEREOF

    US20170340732A1

Cited By

  • Cell line capable of stably expressing porcine PIGR SC fragment and J chain as well as construction method and application of cell line

    CN119979613A